COVIX-19 Rapid Antibody Test Kit Explained
COVIX-19 looks specifically for COVID-19 antibodies in the blood. There are two types of COVID-19 specific antibodies that COVIX-19 detects: IgG and IgM.
Where COVIX-19 differs from standard testing options available is simple. COVIX-19 looks for an immune system response against COVID-19. It does not look for COVID-19 viral material. It is not accurate to compare COVIX-19 to traditional RT-PCR testing from a scientific perspective, as both look for two different signs of infection.
The easiest explanation for this is the analogy "Where there's smoke, there's fire." COVIX-19 looks for the "smoke" specifically from the fire (a byproduct of the infection), whereas RT-PCR testing looks for the "ash" (a typically assumed byproduct of the fire).
There is no rapidly deployable, readily available, and commercially viable test that looks specifically for COVID-19 virus cells.
Immunoglobulin M (IgM) Antibodies
IgM antibodies are created by a body's immune system during the early to mid phases of contracting a virus. In this case, COVIX-19 looks specifically for COVID-19 IgM antibodies during the early to mid phase of infection.
These IgM antibodies are typically first detectable on day 1 to 3 of symptomatic infection.
IgM antibodies usually remain detectable up to 28-days from the onset of the first symptoms.
Immunoglobulin G (IgG) Antibodies
IgG antibodies are the "second line of defence" after IgM antibodies. COVIX-19 typically detects these antibodies during the mid to late stage infection of COVID-19.
IgG antibodies are usually detectable by COVIX-19 around 7 days post-symptomatic infection, and are responsible for long-term immunity and immunological memory.
IgG antibodies usually remain detectable in whole blood samples longer than 45 days post-infection from COVID-19